CDCA4 / SERTAD1 / E2F1 Facilitates Lung Adenocarcinoma Progression by Inhibiting PINK1 /Parkin‐Mediated Mitophagy
IUBMB Life · 2025
DOI: 10.1002/iub.70073 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Jianlong Tan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China. Hauptthemen laut MEDLINE: Mitophagy, Adenocarcinoma of Lung, Cell Cycle Proteins, Ubiquitin-Protein Ligases. Die Arbeit nennt 60 Literaturangaben. Gefördert von: Natural Science Foundation of Changsha Science and Technology Bureau, Hunan Provincial Key Clinical Specialty Construction and Technological Innovation Project, the RENSHU funding of Hunan Provincial People's Hospital.
Abstract (Originalsprache)
Cell division cycle‐associated protein 4 (CDCA4) has the potential to indicate lung adenocarcinoma (LUAD) development, but its regulatory role in mitophagy remains unclear. This study aimed to elucidate the mitophagy regulation and therapeutic implications of CDCA4 in LUAD. CDCA4 expression was significantly elevated in LUAD clinical specimens versus paracancerous tissues and inversely correlated with mitophagy activity. Lentiviral vectors were employed to manipulate established LUAD cells, followed by treatment with chloroquine (CQ; lysosomal inhibitor) and rapamycin (autophagy inducer) in CDCA4‐silenced cells. CDCA4 knockdown elevated total and mitochondrial superoxide levels, disrupted mitochondrial membrane potential, activated the PINK1/Parkin pathway, enhanced LC3‐II conversion, and degraded mitochondrial membrane proteins, collectively promoting mitophagy. Silencing CDCA4 suppressed malignant phenotypes (proliferation/migration), effects reversed by CQ but exacerbated by rapamycin. Mechanistically, CDCA4 interacted with SERTAD1 and E2F1 and stabilized these proteins. The promotion of mitophagy by CDCA4 silencing was impaired by the overexpression of SERTAD1 and E2F1. LUAD cells silencing CDCA4 were injected into immunodeficient mice for in vivo verification. CDCA4‐silenced xenografts exhibited suppressed tumor growth, increased apoptosis, and elevated mitophagy‐related markers. This study identifies the CDCA4/SERTAD1/E2F1 complex as a pivotal mitophagy‐inhibitory hub in LUAD, proposing this axis as a novel predictive and therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
- Department of Respiratory Medicine, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
ORCID-Profile: Weidong Zhang
Förderung
- Natural Science Foundation of Changsha Science and Technology Bureau
- Hunan Provincial Key Clinical Specialty Construction and Technological Innovation Project
- the RENSHU funding of Hunan Provincial People's Hospital
Zitieren
APA
Tan, J., Wang, J., Zhang, W., & Zhang, C. (2025). CDCA4 / SERTAD1 / E2F1 Facilitates Lung Adenocarcinoma Progression by Inhibiting PINK1 /Parkin‐Mediated Mitophagy. IUBMB Life. https://doi.org/10.1002/iub.70073
Vancouver
Tan J, Wang J, Zhang W, Zhang C. CDCA4 / SERTAD1 / E2F1 Facilitates Lung Adenocarcinoma Progression by Inhibiting PINK1 /Parkin‐Mediated Mitophagy. IUBMB Life. 2025. doi:10.1002/iub.70073
BibTeX
@article{Tan2025,
author = {Tan, Jianlong and Wang, Jufen and Zhang, Weidong and Zhang, Cuihua},
title = {CDCA4 / SERTAD1 / E2F1 Facilitates Lung Adenocarcinoma Progression by Inhibiting PINK1 /Parkin‐Mediated Mitophagy},
journal = {IUBMB Life},
year = {2025},
doi = {10.1002/iub.70073}
}
EUVIMED